Skip to main content

Table 2 Comparison of liver function tests at week 4 after initiation of antituberculosis drugs

From: A double-blinded randomized controlled trial of silymarin for the prevention of antituberculosis drug-induced liver injury

 

Silymarin

Placebo

p-value

(N = 27)

(N = 28)

ALT (IU/L)

32 (20, 184)

35 (15, 415)

0.455

AST (IU/L)

26 (14, 219)

29 (13, 386)

0.888

ALP (IU/L)

78 (37, 409)

85 (56, 249)

0.622

GGT (IU/L)

61 (13, 224)

99 (21, 366)

0.215

TP (g/L)

74.2 (25.1, 90.8)

73.3 (48.7, 93.7)

0.920

Alb (g/L)

33.6 (8, 41)

35.0 (19, 69)

0.565

TB (mg/dl)

0.6 (0.2, 2.2)

0.6 (0.2, 6.5)

0.999

DB (mg/dl)

0.3 (0.1, 1.4)

0.3 (0.1, 5.0)

0.999

  1. ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl transpeptidase; TP, total protein; Alb, albumin; TB, total bilirubin; DB, direct bilirubin
  2. Continuous variables reported as median (interquartile range)